Investing in AbbVie Inc. (ABBV)  ➔  Intrinsic value

Prev. close$107.73 
ModelValueUpside
Chepakovich$3.29-97%
Graham-Dodd$0.00-100%
Graham$328.21+205%
Previous Close$107.73  
Valuation MethodValuePotential 
Chepakovich Model$3.29-97%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$328.21+205%recalculate

Articles

Abbvie posted strong sales growth in Q1

2021-05-11   Author: Stock Analyst   Category: Stock analysis

Abbvie released its financial results for the 1st quarter of 2021 on Friday, April 30. What is in the numbers?   [read all]

Skyrizi and Rinvoq Can Help AbbVie Beat Consensus

2021-04-29   Author: Stock Analyst   Category: Stock analysis

One of the leaders in the US pharmaceutical industry, AbbVie, will release its 1Q08 financials on Friday, April 30. What to expect?   [read all]

Patents will keep AbbVie growing

2021-03-09   Author: Stock Analyst   Category: Stock analysis

We have a Buy recommendation for AbbVie with a target price of $120 for December 2021, which provides an upside potential of 18.5% from the current price adjusted for the 2021 dividend.   [read all]

Latest news

Company description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.